Morgan Stanley Maintains Pfizer (PFE) at Equal Weight, Highlights Patent Concerns

Pfizer Inc. (NYSE:PFE) is included among the 10 Innovative Dividend Stocks to Buy Right Now.

Morgan Stanley Maintains Pfizer (PFE) at Equal Weight, Highlights Patent Concerns

On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on the stock. The firm said that Pfizer has reached a settlement with all three Vyndamax generic filers. The agreement extends U.S. exclusivity for Vyndamax to June 1, 2031. The firm said that, based on recent conversations, this outcome sits at the lower end of investor expectations of 2031/2032. The analyst added that the settlement suggests the polymorph patent, which expires in 2035, is “likely not very strong.”

Pfizer developed a form of santonin used to treat intestinal worms. The treatment gained popularity due to its effectiveness. One of its founders, Erhart, used his background in candy-making to add an almond-toffee flavor, which made the medicine easier to take. Around the same time, the company began producing citric acid, an ingredient used in beverages like Coca-Cola. This product became a core part of the business and supported growth over the following decades.

Pfizer Inc. (NYSE:PFE) is a research-based global biopharmaceutical company. It focuses on the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide.

While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best High-Yield Dividend Growth Stocks to Buy Right Now and 10 Large-Cap Stocks That Are On Fire Right Now

Disclosure: None. Follow Insider Monkey on Google News.